An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Hepatocellular Carcinoma
- Liver Metastases
- Non Small Cell Lung Cancer Metastatic
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Parallel with potential crossover from Arm C to Arm B.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Participants with liver cancer will be assigned to Arm A and receive atezolizumab and bevacizumab. Participants with non-small cell lung cancer will be randomized into one of the following arms: Arm B: Atezolizumab and bevacizumab Arm C: Atezolizumab alone Participants randomized to Arm C whose dise...
Participants with liver cancer will be assigned to Arm A and receive atezolizumab and bevacizumab. Participants with non-small cell lung cancer will be randomized into one of the following arms: Arm B: Atezolizumab and bevacizumab Arm C: Atezolizumab alone Participants randomized to Arm C whose disease worsens may be able to cross over to Arm B and receive atezolizumab and bevacizumab together.
Tracking Information
- NCT #
- NCT04563338
- Collaborators
- Hoffmann-La Roche
- Investigators
- Principal Investigator: Adrian Sacher, MD Princess Margaret Cancer Centre
Get Well Soon